Company profile

Ticker
DNA
Exchange
Employees
Incorporated in
Location
Fiscal year end
SEC CIK
IRS number
942347624

Calendar

20 Feb 09
10 Jul 20
31 Dec 20

News

Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: Abbreviated, Abciximab, abetting, accidental, Accretropin, acid, Actimmune, adhering, advisory, Affymetrix, aiding, allegedly, America, ANDA, answered, Antisoma, anytime, Arzerra, ASCO, bankruptcy, BiovaxID, BioVest, Bowel, British, broadly, brought, burdensome, campaign, Cangene, Chancery, CHMP, cited, clarified, commonly, companion, conclusion, cycle, Dacetuzumab, Dear, declaratory, deoxyribonucleic, Deutschland, distraction, docetaxel, draft, duty, economy, efficient, efficiently, EKR, EMEA, endocrine, explain, fiduciary, filtering, FIT, fludarabine, Ford, formal, formulary, frontline, FSP, gastric, GDC, GlycArt, GmbH, grown, Harkonen, Hellmann, hematologic, hematological, hematology, hierarchy, Hoechst, ICC, identical, IMAGE, immunoglobulin, improper, inflammatory, inflation, infliximab, insolvent, instance, intensify, InterMune, intraocular, intravenously, issuable, lag, leukoencephalopathy, LG, lifted, London, low, Lufkin, MabThera, macroeconomic, Marc, Mateo, Median, Medicinal, medicine, methodology, MetMAb, Moody, multifocal, NCCN, neurologic, Neurological, Neurology, North, NSABP, ocrelizumab, outweigh, overseeing, overturned, pendency, permission, Piramed, pivotal, PML, predecessor, presidential, properly, prosecute, prosecutor, provisional, purified, racketeering, radiation, randomized, recession, recipient, recommenced, rely, remeasured, ReoPro, replying, RMS, salable, Sanofi, SATURN, School, Scott, SEC, secondary, shareholder, Similarly, SLE, sNDA, staffing, student, suit, Surgical, thirteenth, thirty, transparency, unaffiliated, uncontrolled, undergoing, uninterrupted, unknown, unobservable, unresolved, unsalable, unsolicited, upheld, urged, urticaria, USA, Ustekinumab, Valtropin, vast, Ventana, view, vigorously, waived, weaker, worse
Removed: absolute, accumulation, aggressive, amending, antitrust, APB, appealing, bearing, BioPharma, body, boyer, bulky, calculation, candidate, Certification, certiorari, Circuit, Citigroup, Computer, consuming, contemplated, convict, debra, deliver, denied, detailed, detectable, diminished, disrupt, disruptive, document, driver, duly, Endowment, entail, enterprise, establishment, exhibit, expensive, flat, furnished, Goldman, grand, heading, herbert, hereof, herewith, Immunex, implementing, Indenture, integration, intensive, introduced, Japanese, Kogyo, lawful, lawfully, lessor, location, meaningful, minimal, nonpayment, obsolete, omitted, page, PDL, plasminogen, power, prompt, promulgated, prospect, Qualifying, ratifying, reaching, recruiting, redacted, reed, rehearing, relocation, resubstitution, rolling, salary, satisfy, shipment, signature, stead, subjected, substitute, thereunto, therewith, tissue, transitioning, true, trustee, undersigned, updating, upfront, virtue, wholly, Xeloda, Zenyaku

Patents

APP
Utility
Formulations with Reduced Degradation of Polysorbate
9 Jul 20
The invention provides methods for making such formulations and methods of using such formulations.
APP
Utility
Methods for Viral Inactivation and Other Adventitious Agents
9 Jul 20
The invention provides for methods of viral inactivation using high temperature short time (HTST) treatment and adjustment of various parameters such that generation of precipitate and depositions of precipitate are reduced and/or minimized.
APP
Utility
TDO2 and IDO1 Inhibitors
9 Jul 20
Presently provided are inhibitors of TD02 and IDOl and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2,3 dioxygenase and indoleamine 2,3-dioxygenase 1; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.
GRANT
Utility
Decreasing lactate level and increasing polypeptide production by down regulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
7 Jul 20
The present invention provides methods and compositions for reducing lactate production and increasing polypeptide production in cultured cells.
APP
Utility
Uses for and Article of Manufacture Including HER2 Dimerization Inhibitor Pertuzumab
2 Jul 20
The present application describes uses for Pertuzumab, a first-in-class HER2 dimerization inhibitor.